| Species |
Human |
| Protein Construction |
VEGF R3/FLT4 (Tyr25-Ile776)
Accession # P35916-1 |
His |
Avi |
| N-term |
|
C-term |
|
| Purity |
> 95% as determined by Bis-Tris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
87.4 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 110-130 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from a 0.22 μm filtered solution in HER-HM403F. |
| Reconstitution |
It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH2O more than 100 μg/ml. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
The purity of VEGF R3/FLT4, His & Avi, Human is greater than 95% as determined by SEC-HPLC.
VEGF R3/FLT4, His & Avi, Humanon Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
| Target Background |
Vascular endothelial growth factor receptor 3 (VEGFR3) is one kind of tyrosine-protein kinase. VEGFR3 acts as a cell-surface receptor for VEGFC and VEGFD. It is a key regulator of lymphatic system development and establishment. VEGFR3 plays important roles in angiogenesis. It is also up-regulated in the endothelium of blood vessels in breast cancer and various other tumors. |
| Synonyms |
VEGFR-3; FLT-4; LMPH1A; PCLFLT41; VEGFR3; FLT-41; PCL |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.
